Skip to main content

Advertisement

SpringerLink
Log in

Alcoholic Hepatitis: Current Management

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Alcoholic hepatitis is an acute manifestation of alcoholic liver disease with mortality as high as 40–50 % in severe cases. Patients usually have a history of prolonged alcohol abuse with or without a known history of liver disease. Although there is significant range in severity at presentation, patients with severe alcoholic hepatitis typically present with anorexia, fatigue, fever, jaundice, and ascites. The use of either pentoxifylline or corticosteroids in those with severe disease (Maddrey’s discriminate function >32) has significant mortality benefit. The addition of N-acetylcysteine to corticosteroids decreases the incidences of hepatorenal syndrome, infection, and short-term mortality, but does not appear to significantly affect 6-month mortality. Nutritional support with high-calorie, high-protein diet is recommended in all patients screening positive for malnutrition. Liver transplantation for a highly selected group of patients with severe alcoholic hepatitis may be an option in the future, but is not currently recommended or available at most transplant institutions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. Dionysos Study Group Gut. 1997;41:845–850.

    CAS  Google Scholar 

  2. Becker U, Deis A, Sørensen TI, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study Hepatology. 1996;23:1025–1029.

    CAS  Google Scholar 

  3. Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol. 2001;35:531–537.

    Article  PubMed  CAS  Google Scholar 

  4. Tsukamoto H, Machida K, Dynnyk A, Mkrtchyan H. “Second hit” models of alcoholic liver disease. Semin Liver Dis. 2009;29:178–187.

    Article  PubMed  CAS  Google Scholar 

  5. Basra S, Anand BS. Definition, epidemiology and magnitude of alcoholic hepatitis. World J Hepatol. 2011;3:108–113.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997;25:108–111.

    Article  PubMed  CAS  Google Scholar 

  7. Dhanda AD, Collins PL, McCune CA. Is liver biopsy necessary in the management of alcoholic hepatitis? World J Gastroenterol. 2013;19:7825–7829.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Loft S, Olesen KL, Døssing M. Increased susceptibility to liver disease in relation to alcohol consumption in women. Scand J Gastroenterol. 1987;22:1251–1256.

    Article  PubMed  CAS  Google Scholar 

  9. Grant BF, Dufour MC, Harford TC. Epidemiology of alcoholic liver disease. Semin Liver Dis. 1988;8:12–25.

    Article  PubMed  CAS  Google Scholar 

  10. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360:2758–2769.

    Article  PubMed  CAS  Google Scholar 

  11. Lischner MW, Alexander JF, Galambos JT. Natural history of alcoholic hepatitis. I. The acute disease. Am J Dig Dis. 1971;16:481–494.

    Article  PubMed  CAS  Google Scholar 

  12. Altamirano J, Miquel R, Katoonizadeh A, et al. A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology. 2014;146:1231–1239.e6.

  13. Mookerjee RP, Lackner C, Stauber R, et al. The role of liver biopsy in the diagnosis and prognosis of patients with acute deterioration of alcoholic cirrhosis. J Hepatol. 2011;55:1103–1111.

    Article  PubMed  Google Scholar 

  14. Porter HP, Simon FR, Pope CE 2nd, Volwiler W, Fenster LF. Corticosteroid therapy in severe alcoholic hepatitis. A double-blind drug trial. N Engl J Med. 1971;284:1350–1355.

    Article  PubMed  CAS  Google Scholar 

  15. Helman RA, Temko MH, Nye SW, Fallon HJ. Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy Ann Intern Med. 1971;74:311–321.

    CAS  Google Scholar 

  16. Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978;75:193–199.

    PubMed  CAS  Google Scholar 

  17. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864–871.

    Article  PubMed  CAS  Google Scholar 

  18. Salerno F, Merli M, Cazzaniga M, et al. MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. J Hepatol. 2002;36:494–500.

    Article  PubMed  Google Scholar 

  19. Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005;41:353–358.

    Article  PubMed  Google Scholar 

  20. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–470.

    Article  PubMed  CAS  Google Scholar 

  21. Kadian M, Kakkar R, Dhar M, Kaushik RM. MELD score versus Maddrey Discriminant Function score in assessing short-term outcome in alcoholic hepatitis. J Gastroenterol Hepatol. 2014;29:581–588.

  22. Monsanto P, Almeida N, Lrias C, Pina JE, Sofia C. Evaluation of MELD score and Maddrey discriminant function for mortality prediction in patients with alcoholic hepatitis. Hepatogastroenterology. 2013;60:1089–1094.

    PubMed  CAS  Google Scholar 

  23. Sheth M, Riggs M, Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol. 2002;2:2.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Forrest EH, Evans CD, Stewart S, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut. 2005;54:1174–1179.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  25. Forrest EH, Morris AJ, Stewart S, et al. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut. 2007;56:1743–1746.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  26. Dominguez M, Rincón D, Abraldes JG, et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol. 2008;103:2747–2756.

    Article  PubMed  Google Scholar 

  27. Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007;45:1348–1354.

    Article  PubMed  CAS  Google Scholar 

  28. Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis—a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther. 2008;27:1167–1178.

    Article  PubMed  CAS  Google Scholar 

  29. Carithers RL Jr, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med. 1989;110:685–690.

    Article  PubMed  Google Scholar 

  30. Mathurin P, O’Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2011;60:255–260.

    Article  PubMed  CAS  Google Scholar 

  31. Louvet A, Wartel F, Castel H, et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology. 2009;137:541–548.

    Article  PubMed  CAS  Google Scholar 

  32. Louvet A, Diaz E, Dharancy S, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol. 2008;48:465–470.

  33. Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med. 1990;113:299–307.

    Article  PubMed  CAS  Google Scholar 

  34. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T. Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial Gastroenterology. 2000;119:1637–1648.

    CAS  Google Scholar 

  35. De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol. 2009;15:1613–1619.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  36. Sidhu SS, Goyal O, Singla P, et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Dig Dis Sci. 2012;57:1664–1671.

    Article  PubMed  CAS  Google Scholar 

  37. Mathurin P, Louvet A, Duhamel A, et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA. 2013;310:1033–1041.

    Article  PubMed  CAS  Google Scholar 

  38. Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011;365:1781–1789.

    Article  PubMed  CAS  Google Scholar 

  39. Strieter RM, Kunkel SL, Bone RC. Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med. 1993;21:S447–S463.

    Article  PubMed  CAS  Google Scholar 

  40. Iimuro Y, Gallucci RM, Luster MI, Kono H, Thurman RG. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology. 1997;26:1530–1537.

    Article  PubMed  CAS  Google Scholar 

  41. Sharma P, Kumar A, Sharma BC, Sarin SK. Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: an open label trial. J Hepatol. 2009;50:584–591.

    Article  PubMed  CAS  Google Scholar 

  42. Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol. 2003;38:419–425.

    Article  PubMed  CAS  Google Scholar 

  43. Spahr L, Rubbia-Brandt L, Frossard JL, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol. 2002;37:448–455.

    Article  PubMed  CAS  Google Scholar 

  44. Naveau S, Chollet-Martin S, Dharancy S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis Hepatology. 2004;39:1390–1397.

    CAS  Google Scholar 

  45. Boetticher NC, Peine CJ, Kwo P, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology. 2008;135:1953–1960.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  46. Mendenhall CL, Moritz TE, Roselle GA, et al. Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment. The VA Cooperative Study Group #275. JPEN J Parenter Enteral Nutr. 1995;19:258–265.

    Article  PubMed  CAS  Google Scholar 

  47. Mendenhall C, Roselle GA, Gartside P, Moritz T. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration Cooperative Studies. Alcohol Clin Exp Res. 1995;19:635–641.

    Article  PubMed  CAS  Google Scholar 

  48. Mendenhall CL, Anderson S, Weesner RE, Goldberg SJ, Crolic KA. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am J Med. 1984;76:211–222.

    Article  PubMed  CAS  Google Scholar 

  49. O’Shea RS, Dasarathy S, McCullough AJ. Diseases PGCotAAftSoL, gastroenterology PPCotACo. Alcoholic liver disease. Hepatology. 2010;51:307–328.

    Article  PubMed  Google Scholar 

  50. Cabré E, Rodríguez-Iglesias P, Caballería J, et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology. 2000;32:36–42.

    Article  PubMed  Google Scholar 

  51. Alvarez MA, Cabre E, Lorenzo-Zuniga V, Montoliu S, Planas R, Gassull MA. Combining steroids with enteral nutrition: a better therapeutic strategy for severe alcoholic hepatitis? Results of a pilot study. Eur J Gastroenterol Hepatol. 2004;16:1375–1380.

    Article  PubMed  CAS  Google Scholar 

  52. Neuberger J, Adams D, MacMaster P, Maidment A, Speed M. Assessing priorities for allocation of donor liver grafts: survey of public and clinicians. BMJ. 1998;317:172–175.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  53. Deruytter E, Van Steenkiste C, Trépo E, et al. Liver transplantation for alcoholic liver disease: a retrospective analysis of recidivism, survival and risk factors predisposing to alcohol relapse. Acta Gastroenterol Belg. 2013;76:282–290.

    PubMed  Google Scholar 

  54. Rodrigue JR, Hanto DW, Curry MP. The alcohol relapse risk assessment: a scoring system to predict the risk of relapse to any alcohol use after liver transplant. Prog Transpl. 2013;23:310–318.

    Article  Google Scholar 

  55. Lucey MR. Liver transplantation in patients with alcoholic liver disease. Liver Transpl. 2011;17:751–759.

    Article  PubMed  Google Scholar 

  56. McCallum S, Masterton G. Liver transplantation for alcoholic liver disease: a systematic review of psychosocial selection criteria. Alcohol Alcohol. 2006;41:358–363.

    Article  PubMed  Google Scholar 

  57. Rice JP, Lucey MR. Should length of sobriety be a major determinant in liver transplant selection? Curr Opin Organ Transpl. 2013;18:259–264.

    Article  Google Scholar 

  58. Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011;365:1790–1800.

    Article  PubMed  CAS  Google Scholar 

  59. DiMartini A, Day N, Dew MA, et al. Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease. Liver Transpl. 2006;12:813–820.

    Article  PubMed  Google Scholar 

  60. Pageaux GP, Bismuth M, Perney P, et al. Alcohol relapse after liver transplantation for alcoholic liver disease: does it matter? J Hepatol. 2003;38:629–634.

    Article  PubMed  CAS  Google Scholar 

  61. Potts JR, Goubet S, Heneghan MA, Verma S. Determinants of long-term outcome in severe alcoholic hepatitis. Aliment Pharmacol Ther. 2013;38:584–595.

    Article  PubMed  CAS  Google Scholar 

  62. Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370:1915–1922.

    Article  PubMed  CAS  Google Scholar 

  63. Addolorato G, Leggio L, Ferrulli A, et al. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol. 2011;46:312–317.

    Article  PubMed  CAS  Google Scholar 

  64. Brennan JL, Leung JG, Gagliardi JP, Rivelli SK, Muzyk AJ. Clinical effectiveness of baclofen for the treatment of alcohol dependence: a review. Clin Pharmacol. 2013;5:99–107.

    PubMed  PubMed Central  Google Scholar 

  65. Leggio L, Ferrulli A, Zambon A, et al. Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. Addict Behav. 2012;37:561–564.

    Article  PubMed  CAS  Google Scholar 

  66. Yoshimura A, Kimura M, Nakayama H, et al. Efficacy of disulfiram for the treatment of alcohol dependence assessed with a multicenter randomized controlled trial. Alcohol Clin Exp Res. 2014;38:572–578.

  67. Iber FL, Lee K, Lacoursiere R, Fuller R. Liver toxicity encountered in the Veterans Administration trial of disulfiram in alcoholics. Alcohol Clin Exp Res. 1987;11:301–304.

    Article  PubMed  CAS  Google Scholar 

  68. Rubio G, Jiménez-Arriero MA, Ponce G, Palomo T. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol Alcohol. 2001;36:419–425.

    Article  PubMed  CAS  Google Scholar 

  69. Pettinati HM, Silverman BL, Battisti JJ, Forman R, Schweizer E, Gastfriend DR. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence. Alcohol Clin Exp Res. 2011;35:1804–1811.

    Article  PubMed  CAS  Google Scholar 

  70. Dranitsaris G, Selby P, Negrete JC. Meta-analyses of placebo-controlled trials of acamprosate for the treatment of alcohol dependence: impact of the combined pharmacotherapies and behavior interventions study. J Addict Med. 2009;3:74–82.

    Article  PubMed  CAS  Google Scholar 

  71. Mann K, Kiefer F, Smolka M, et al. Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study. Alcohol Clin Exp Res. 2009;33:674–683.

    Article  PubMed  CAS  Google Scholar 

  72. Anton RF, O’Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003–2017.

    Article  PubMed  CAS  Google Scholar 

  73. Berner MM, Wahl S, Brueck R et al. The place of additional individual psychotherapy in the treatment of alcoholism: a randomized controlled study in nonresponders to anticraving medication-results of the PREDICT study. Alcohol Clin Exp Res. 2014;38:1118–1125.

  74. Ge X, Lu Y, Leung TM, Sørensen ES, Nieto N. Milk osteopontin, a nutritional approach to prevent alcohol-induced liver injury. Am J Physiol Gastrointest Liver Physiol. 2013;304:G929–G939.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  75. Ge X, Leung TM, Arriazu E, et al. Osteopontin binding to lipopolysaccharide lowers tumor necrosis factor-α and prevents early alcohol-induced liver injury in mice. Hepatology. 2014;59:1600–1616.

    Article  PubMed  CAS  Google Scholar 

  76. Vlachogiannakos J, Saveriadis AS, Viazis N, et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther. 2009;29:992–999.

    Article  PubMed  CAS  Google Scholar 

  77. Gao B. Hepatoprotective and anti-inflammatory cytokines in alcoholic liver disease. J Gastroenterol Hepatol. 2012;27:89–93.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  78. Stadlbauer V, Mookerjee RP, Hodges S, Wright GA, Davies NA, Jalan R. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol. 2008;48:945–951.

    Article  PubMed  CAS  Google Scholar 

  79. Kalambokis GN, Mouzaki A, Rodi M, Tsianos EV. Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia. Liver Int. 2012;32:467–475.

    PubMed  CAS  Google Scholar 

  80. Kalambokis GN, Tsianos EV. Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis. Hepatology. 2012;55:655–656.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA, 52242-1081, USA

    Erin K. J. Spengler, Jeffrey Dunkelberg & Ron Schey

Authors
  1. Erin K. J. Spengler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey Dunkelberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ron Schey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ron Schey.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Spengler, E.K.J., Dunkelberg, J. & Schey, R. Alcoholic Hepatitis: Current Management. Dig Dis Sci 59, 2357–2366 (2014). https://doi.org/10.1007/s10620-014-3173-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-014-3173-8

Keywords

Search

Navigation